HCW Biologics Inc. last reported quarterly results on Aug 14, 2026, for Q2 FY2026 (the quarter ended Jun 30, 2026): revenue of $121,730 (+1758.5% year over year) and diluted EPS of -$11.58. It usually reports 44–45 days after a quarter ends. Based on that pattern, the next release is estimated for around Nov 13, 2026.
Results for Q3 FY2026, the quarter ending around Sep 30, 2026. Expected on a Friday. Based on last year's release for the same quarter on Nov 14, 2025. This is an estimate, not a date the company has announced.
Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 44–45 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.
| Released | Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|---|
|
Aug 14, 2026
45 days after quarter end
|
Q2 FY2026
ended Jun 30, 2026
|
0
+1758.5%
|
-5
-170.7%
|
-11.58
+71.6%
|
|
May 14, 2026
44 days after quarter end
|
Q1 FY2026
ended Mar 31, 2026
|
6
+128231.7%
|
3
+258.1%
|
1.39
+111.8%
|
|
Nov 14, 2025
45 days after quarter end
|
Q3 FY2025
ended Sep 30, 2025
|
0
-96.3%
|
-5
-16.7%
|
-2.02
+51.1%
|
|
Aug 14, 2025
45 days after quarter end
|
Q2 FY2025
ended Jun 30, 2025
|
0
-98.9%
|
-2
+87.4%
|
-40.72
-152.0%
|
|
May 15, 2025
45 days after quarter end
|
Q1 FY2025
ended Mar 31, 2025
|
0
-99.6%
|
-2
+70.6%
|
-11.80
-5800.0%
|
|
Nov 14, 2024
45 days after quarter end
|
Q3 FY2024
ended Sep 30, 2024
|
0
-50.0%
|
-4
+21.0%
|
-4.13
-2850.0%
|
|
Aug 14, 2024
45 days after quarter end
|
—
ended Jun 30, 2024
|
—
|
—
|
—
|
|
Apr 1, 2024
1 days after quarter end
|
—
ended Mar 31, 2024
|
—
|
—
|
—
|
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- HCWB (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Miramar, FL
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1828673
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.